The spleen tyrosine kinase (SYK): A crucial therapeutic target for diverse liver diseases

The spleen tyrosine kinase (SYK): A crucial therapeutic target for diverse liver diseases

Spleen tyrosine kinase (SYK) is an enigmatic protein tyrosine kinase, and involved in signal transduction related with lots of cellular processes. It’s highly expressed in the cells of hematopoietic origin and acts as an important therapeutic target in the treatment of autoimmune diseases and allerg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yaping Zhao, Rongrong Liu, Miaomiao Li, Pengfei Liu
Formato:	Artículo
Lenguaje:	English
Publicado:	Elsevier 2022-12-01
Colección:	Heliyon
Materias:	Spleen tyrosine kinase (SYK) Liver diseases Small molecule inhibitor Therapy target
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S2405844022034181

Ejemplares similares

The selective inhibition of the Syk tyrosine kinase ameliorates experimental autoimmune arthritis
por: Eszter Káposztás, et al.
Publicado: (2023-12-01)

Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib
por: Nichola Cooper, et al.
Publicado: (2023-01-01)

Biochemical characterization of spleen tyrosine kinase (SYK) isoforms in platelets
por: Pankaj Kumar Singh, et al.
Publicado: (2023-12-01)

Activation of spleen tyrosine kinase (SYK) contributes to neuronal pyroptosis and cognitive impairment in diabetic mice via the NLRP3/Caspase-1/GSDMD signaling pathway
por: Chenglong Zhou, et al.
Publicado: (2024-12-01)

Identification of high-performing antibodies for tyrosine-protein kinase SYK for use in Western Blot, immunoprecipitation and immunofluorescence [version 3; peer review: 2 approved]
por: Carl Laflamme, et al.
Publicado: (2024-06-01)

Hematopoietic or Osteoclast-Specific Deletion of Syk Leads to Increased Bone Mass in Experimental Mice
por: Dániel Csete, et al.
Publicado: (2019-04-01)

Spleen tyrosine kinase (SYK) signals are implicated in cardio-cerebrovascular diseases
por: Mohan Li, et al.
Publicado: (2023-05-01)

Spleen tyrosine kinase mediates the γδTCR signaling required for γδT cell commitment and γδT17 differentiation
por: Ryunosuke Muro, et al.
Publicado: (2023-01-01)

Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis
por: Christopher W. Pohlmeyer, et al.
Publicado: (2021-03-01)

Anti-microbial cetylpyridinium chloride suppresses mast cell function by targeting tyrosine phosphorylation of Syk kinase
por: Bright Obeng, et al.
Publicado: (2024-12-01)

Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
por: Kata P. Szilveszter, et al.
Publicado: (2019-08-01)

S-Layer From Lactobacillus brevis Modulates Antigen-Presenting Cell Functions via the Mincle-Syk-Card9 Axis
por: Mariano Prado Acosta, et al.
Publicado: (2021-03-01)

A spleen tyrosine kinase inhibitor attenuates the proliferation and migration of vascular smooth muscle cells
por: Hyang‑Hee Seo, et al.

Spleen Tyrosine Kinase Is a Critical Regulator of Neutrophil Responses to <italic toggle="yes">Candida</italic> Species
por: Paige E. Negoro, et al.
Publicado: (2020-06-01)

Immunomodulatory role of spleen tyrosine kinase in chronic inflammatory and autoimmune diseases
por: Yaqi Zhou, et al.
Publicado: (2023-07-01)

CCL4‐mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease
por: Wenbin Gong, et al.
Publicado: (2021-02-01)

Inhibition of Spleen Tyrosine Kinase Restores Glucocorticoid Sensitivity to Improve Steroid-Resistant Asthma
por: Qian Liu, et al.
Publicado: (2022-05-01)

Systematic analysis of spleen tyrosine kinase expression and its clinical outcomes in various cancers
por: Akram I Alwithenani, et al.
Publicado: (2020-01-01)

Phosphorylation of (Ser 291) in the linker insert of Syk negatively regulates ITAM signaling in platelets
por: Carol Dangelmaier, et al.
Publicado: (2024-12-01)

The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients
por: Jing Wang, et al.
Publicado: (2023-02-01)

Expression of variant isoforms of the tyrosine kinase SYK differentially regulates cervical cancer progression through PI3K/AKT pathway
por: Bingjie Lin, et al.
Publicado: (2024-11-01)

Three Novel Players: PTK2B, SYK, and TNFRSF21 Were Identified to Be Involved in the Regulation of Bovine Mastitis Susceptibility via GWAS and Post-transcriptional Analysis
por: Fan Yang, et al.
Publicado: (2019-08-01)

Development of SYK NanoBRET cellular target engagement assays for gain–of–function variants
por: Jacob L. Capener, et al.
Publicado: (2024-07-01)

Effects of a spleen tyrosine kinase inhibitor on progression of the lupus nephritis in mice
por: Maki Kitai, et al.
Publicado: (2017-05-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
por: Yi-fan Chen, et al.
Publicado: (2011-12-01)

Tyrosine kinase targeting: A potential therapeutic strategy for diabetes
por: Mohammad Althubiti
Publicado: (2022-01-01)

Spleen tyrosine kinase inhibitors disrupt human neutrophil swarming and antifungal functions
por: Alex Hopke, et al.
Publicado: (2025-01-01)

Stress Granules Modulate SYK to Cause Microglial Cell Dysfunction in Alzheimer's Disease
por: Soumitra Ghosh, et al.
Publicado: (2015-11-01)

Fluorescent Tracking of Yeast Division Clarifies the Essential Role of Spleen Tyrosine Kinase in the Intracellular Control of Candida glabrata in Macrophages
por: Zeina Dagher, et al.
Publicado: (2018-05-01)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
por: Chen-Yu Hu, et al.
Publicado: (2019-12-01)

Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
por: Xuejin Ou, et al.
Publicado: (2024-09-01)

Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization
por: Halil Ibrahim Onder, et al.
Publicado: (2014-04-01)

Receptor Tyrosine Kinase Signaling Involves <i>Echinococcus</i>–Host Intercommunication: A Potential Therapeutic Target in Hepatic Echinococcosis
por: Haijun Gao, et al.
Publicado: (2024-08-01)

Advances in studies of tyrosine kinase inhibitors and their acquired resistance
por: Qinlian Jiao, et al.
Publicado: (2018-02-01)

Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
por: Sareshma Sudhesh Dev, et al.
Publicado: (2021-11-01)

Exploring receptor tyrosine kinases-inhibitors in Cancer treatments
por: D. Samuel Metibemu, et al.
Publicado: (2019-12-01)

Recent developments in receptor tyrosine kinases targeted anticancer therapy
por: Samir H. Raval, et al.
Publicado: (2016-01-01)

Complement receptor-3 negatively regulates the phagocytosis of degenerated myelin through tyrosine kinase Syk and cofilin
por: Hadas Smadar, et al.
Publicado: (2012-07-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu H, et al.
Publicado: (2019-07-01)

Therapeutic potential of tyrosine-protein kinase MET in osteosarcoma
por: Ming Zeng, et al.
Publicado: (2024-03-01)